BPC-157 Reconstitution Vial 5 mg BAC Water 2 mL Concentration 2,500 mcg/mL 250 mcg 10 units (0.10 mL) 500 mcg 20 units (0.20 mL) Vial 10 mg BAC Water 2 mL Concentration 5,000 mcg/mL 250 mcg 5 units (0.05 mL) 500 mcg 10 units (0.10 mL) TB-500 Reconstitution Vial 5 mg BAC Water 1 mL Concentration 5 mg/mL 2.5 mg 50 units (0.50 mL) 5 mg 100 units (1.00 mL) Vial 10 mg BAC Water 2 mL Concentration 5 mg/mL 2.5 mg 50 units (0.50 mL) 5 mg 100 units (1.00 mL) GHK-Cu Reconstitution Vial 50 mg BAC Water 5 mL Concentration 10 mg/mL 1 mg 10 units (0.10 mL) 2 mg 20 units (0.20 mL) Vial 100 mg BAC Water 10 mL Concentration 10 mg/mL 1 mg 10 units (0.10 mL) 2 mg 20 units (0.20 mL) Math Verification BPC-157: 5,000 mcg 2 mL = 2,500 mcg/mL 500 mcg = 0.20 mL = 20 units

The following adverse effects were reported in patients receiving semaglutide injection or oral tablets across all clinical trials and at incidences higher than with placebo: nausea (11% to 44%), vomiting (5% to 24%), diarrhea (8.5% to 30%), abdominal pain (5.7% to 20%), abdominal distention (2% to 7%), constipation (3.1% to 24%), dyspepsia (0.6% to 9%), decreased appetite (6% to 9%), eructation (0.6% to 7%), flatulence (0.4% to 6%), gastroesophageal reflux disease (1.5% to 5%), gastroenteritis (4% to 6%), and gastritis (0.4% to 4%)
Oral Capsules or Liquids: Used mainly for gut health and digestive issues
These products are not intended for human consumption, medical treatment, or veterinary use